This website is intended for US Healthcare Professionals.

Skip to main content

This site is intended for US audience. Please verify you are a US Healthcare Professional.

YES, I am a US Healthcare Professional

NO, I am not a US Healthcare Professional

Innovation Is Only As Big
As the People You Reach

Inobrodib

is an investigational therapy bringing
cancer research to more patients—
no matter where they are

Innovation Is Only As Big As the People You Reach

Inobrodib

is an investigational therapy bringing cancer research to more patients— no matter where they are

The state of MM

Multiple myeloma (MM) is a disease marked by significant disparities related to race, socioeconomic status, geographic location, and other factors that can create barriers to care.1-6 While the past decade has ushered in groundbreaking advances in MM treatment, many of these innovations remain out of reach.6,7 The increasing complexity of therapies has only added to the barriers,5 highlighting the urgent need for more equitable, accessible solutions.

What is inobrodib?

Inobrodib is an investigational, oral, first-in-class p300/CBP inhibitor drug. It’s currently being studied in combination with other MM therapies.8,9

Targeting resistance

Immunomodulatory drug (IMiD®) therapy is a cornerstone of early-line MM treatment,7 but once patients become refractory, treatment options can become complex and more limited.10 This loss of sensitivity to IMiDs like pomalidomide marks a critical inflection point in treatment sequencing. One mechanism contributing to this resistance is maintained expression of MYC, an oncogenic transcription factor crucial for myeloma cell viability.11-13

Inobrodib is being evaluated in clinical trials to determine whether it can help reestablish sensitivity to IMiD agents, including pomalidomide.

Because IMiD agents are oral, widely used, and increasingly available as generics, resensitizing patients to this class could help expand access to effective and convenient treatment—especially for those outside of specialized care settings.

Clinical trials with
Inobrodib

The inobrodib clinical trials are designed to evaluate all-oral treatment regimens.9 The manageable administration of these regimens may make community-based clinics well suited to participate, helping expand access and bring trials closer to where patients live and receive care.

PARTICIPATE

For more information about patient enrollment or how to register your clinic as a trial site, please send an email to DOMMINO@cellcentric.com

VISIT

You can also find out more by visiting ClinicalTrials.gov

The state of MM

Multiple myeloma (MM) is a disease marked by significant disparities related to race, socioeconomic status, geographic location, and other factors that can create barriers to care.1-6 While the past decade has ushered in groundbreaking advances in MM treatment, many of these innovations remain out of reach.6,7 The increasing complexity of therapies has only added to the barriers,5 highlighting the urgent need for more equitable, accessible solutions.

PARTICIPATE

For more information about patient enrollment or how to register your clinic as a trial site, please send an email to DOMMINO@cellcentric.com

VISIT

You can also find out more by visiting ClinicalTrials.gov

What is inobrodib?

Inobrodib is an investigational, oral, first-in-class p300/CBP inhibitor drug. It’s currently being studied in combination with other MM therapies.8,9

Targeting resistance

Immunomodulatory drug (IMiD®) therapy is a cornerstone of early-line MM treatment,7 but once patients become refractory, treatment options can become complex and more limited.10 This loss of sensitivity to IMiDs like pomalidomide marks a critical inflection point in treatment sequencing. One mechanism contributing to this resistance is maintained expression of MYC, an oncogenic transcription factor crucial for myeloma cell viability.11-13

Inobrodib is being evaluated in clinical trials to determine whether it can help reestablish sensitivity to IMiD agents, including pomalidomide.

Because IMiD agents are oral, widely used, and increasingly available as generics, resensitizing patients to this class could help expand access to effective and convenient treatment—especially for those outside of specialized care settings.

Clinical trials with
Inobrodib

The inobrodib clinical trials are designed to evaluate all-oral treatment regimens.9 The manageable administration of these regimens may make community-based clinics well suited to participate, helping expand access and bring trials closer to where patients live and receive care.

IMiD® is a registered trademark of Celgene Corporation, a Bristol Myers Squibb company.

References: 1. Ailawadhi S, Parikh K, Abouzaid S, et al. Racial disparities in treatment patterns and outcomes among patients with multiple myeloma: a SEER-Medicare analysis. Blood Adv. 2019;3(20):2986-2994. 2. Bhatnagar V, Wu Y, Goloubeva OG, et al. Disparities in black and white patients with multiple myeloma referred for autologous hematopoietic transplantation: a single center study. Cancer. 2015;121(7):1064-1070. 3. Fiala MA, Finney JD, Liu J, et al. Socioeconomic status is independently associated with overall survival in patients with multiple myeloma. Leuk Lymphoma. 2015;56(9):2643-2649. 4. Testamark S, Verbyla A, Robinson M, Voorhees  PM, Bhutani M. Rural‑urban and racial trends in survival of patients with multiple myeloma: 1975‑2019 Surveillance, Epidemiology, and End Results (SEER) Analysis. Blood. 2023;142(suppl 1 ):1977. 5. Lu R, Tariman JD, Catamero D, Hillengass M, Noonan K. Diversity, equity, and inclusion in multiple myeloma: a call to action. J Adv Pract Oncol. Published online July 22, 2024. doi:10.6004/jadpro.2024.15.8.10 6. Gasoyan H, Fiala MA, Doering M, Vij R, Halpern M, Colditz GA. Disparities in multiple myeloma treatment patterns in the United States: a systematic review. Clin Lymphoma Myeloma Leuk. 2023;23(11):e420-e427. 7. Dima D, Jiang D, Singh DJ, et al. Multiple myeloma therapy: emerging trends and challenges. Cancers (Basel). 2022;14(17):4082. doi:10.3390/cancers14174082 8. Searle E, Cavet J, Campbell  V, et al. Tolerability and clinical activity of novel first-in-class oral agent, inobrodib (CCS1477), in combination with pomalidomide and dexamethasone in relapsed/refractory multiple myeloma. Blood. 2024;144(suppl 1):1023. 9. A phase II, open-label, multicenter study of inobrodib in combination with pomalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma [unpublished study protocol]. CellCentric Limited; 2025. 10. Heimberg L, Knop S. Updated perspectives on the management of relapsed and refractory multiple myeloma. Oncol Res Treat. 2021;44(12):682-689. 11. Davis LN, Walker ZJ, Reiman LT, et al. MYC inhibition potentiates CD8+ T cells against multiple myeloma and overcomes immunomodulatory drug resistance. Clin Cancer Res. 2024;30(14):3023-3035. 12. Holien T, Våtsveen TK, Hella H, Waage A, Sundan A. Addiction to c-MYC in multiple myeloma. Blood. 2012;120(12):2450-2453. 13. Wang  K, Baird L, Yamamoto M. The clinical-grade CBP/p300 inhibitor CCS1477 represses the global NRF2-dependent cytoprotective transcription program and re-sensitizes cancer cells to chemotherapeutic drugs. Free Radical Biol Med. 2025;233:102-117.